Axsome Therapeutics, Inc.
NASDAQAxsome Therapeutics heads into its May 4 Q1 report as one of the more bullishly positioned CNS names in the market, with the stock up 22% over the past month and analyst targets rising in lockstep. The analyst community is nearly unanimous in its optimism. All 16 covering analysts carry Buy-equivalent ratings, with a mean price target near $230 — implying roughly 11% upside from…
Snapshot as of 8 May 2026
Axsome Therapeutics heads into its May 4 Q1 report as one of the more bullishly positioned CNS names in the market, with the stock up 22% over the past month and analyst targets rising in lockstep. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AXSM — free to start on ORTEX.
Sign up for free →Open AXSM on ORTEX